West Pharmaceutical Services (NYSE:WST) Trading Up 4.3%

West Pharmaceutical Services, Inc. (NYSE:WST)’s share price was up 4.3% during mid-day trading on Thursday . The company traded as high as $313.92 and last traded at $310.32. Approximately 61,053 shares changed hands during trading, a decline of 89% from the average daily volume of 556,240 shares. The stock had previously closed at $297.61.

West Pharmaceutical Services Stock Down 0.4 %

The firm’s 50 day moving average price is $309.69 and its 200-day moving average price is $343.81. The company has a current ratio of 2.34, a quick ratio of 1.68 and a debt-to-equity ratio of 0.03. The company has a market cap of $22.75 billion, a P/E ratio of 41.38, a price-to-earnings-growth ratio of 10.79 and a beta of 1.00.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.22). The business had revenue of $702.10 million during the quarter, compared to the consensus estimate of $729.36 million. West Pharmaceutical Services had a net margin of 18.25% and a return on equity of 19.17%. West Pharmaceutical Services’s revenue was down 6.9% compared to the same quarter last year. During the same period in the previous year, the business posted $2.11 earnings per share. As a group, equities research analysts expect that West Pharmaceutical Services, Inc. will post 6.44 EPS for the current year.

Insider Buying and Selling at West Pharmaceutical Services

In other news, SVP Silji Abraham sold 1,800 shares of the business’s stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $330.78, for a total transaction of $595,404.00. Following the completion of the transaction, the senior vice president now directly owns 2,860 shares in the company, valued at approximately $946,030.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, VP Charles Witherspoon sold 1,029 shares of the firm’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $300.00, for a total transaction of $308,700.00. Following the sale, the vice president now owns 1,478 shares of the company’s stock, valued at approximately $443,400. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Silji Abraham sold 1,800 shares of the business’s stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $330.78, for a total value of $595,404.00. Following the completion of the transaction, the senior vice president now directly owns 2,860 shares of the company’s stock, valued at $946,030.80. The disclosure for this sale can be found here. Insiders own 0.53% of the company’s stock.

Institutional Investors Weigh In On West Pharmaceutical Services

A number of hedge funds have recently modified their holdings of WST. Fidelis Capital Partners LLC bought a new stake in West Pharmaceutical Services during the 1st quarter worth approximately $27,000. Crewe Advisors LLC boosted its holdings in shares of West Pharmaceutical Services by 322.7% in the second quarter. Crewe Advisors LLC now owns 93 shares of the medical instruments supplier’s stock valued at $31,000 after buying an additional 71 shares during the period. Quarry LP increased its position in shares of West Pharmaceutical Services by 155.3% during the fourth quarter. Quarry LP now owns 97 shares of the medical instruments supplier’s stock worth $34,000 after acquiring an additional 59 shares in the last quarter. Hazlett Burt & Watson Inc. bought a new stake in shares of West Pharmaceutical Services during the first quarter worth $40,000. Finally, Northwest Investment Counselors LLC acquired a new stake in shares of West Pharmaceutical Services during the first quarter worth $40,000. Institutional investors and hedge funds own 93.90% of the company’s stock.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.